Literature DB >> 23749295

Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis.

Valentina Catzola, Alessandra Battaglia, Alexia Buzzonetti, Marco Fossati, Flavia Scuderi, Andrea Fattorossi, Amelia Evoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23749295     DOI： 10.1007/s00415-013-6987-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  14 in total

1.  Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Francesca Ciaraffa; Giovanni Scambia; Amelia Evoli
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

2.  Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

Authors:  P P Sfikakis; V L Souliotis; K G Fragiadaki; H M Moutsopoulos; J N Boletis; A N Theofilopoulos
Journal:  Clin Immunol       Date:  2007-01-31       Impact factor: 3.969

3.  Three-color flow cytometry detection of intracellular cytokines in peripheral blood mononuclear cells: comparative analysis of phorbol myristate acetate-ionomycin and phytohemagglutinin stimulation.

Authors:  J Baran; D Kowalczyk; M Ozóg; M Zembala
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Long-lasting treatment effect of rituximab in MuSK myasthenia.

Authors:  J Díaz-Manera; E Martínez-Hernández; L Querol; R Klooster; R Rojas-García; X Suárez-Calvet; J L Muñoz-Blanco; C Mazia; K R Straasheijm; E Gallardo; C Juárez; J J Verschuuren; I Illa
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

5.  Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development.

Authors:  Alessandra Battaglia; Alexia Buzzonetti; Cinzia Baranello; Mara Fanelli; Marco Fossati; Valentina Catzola; Giovanni Scambia; Andrea Fattorossi
Journal:  Immunology       Date:  2013-05       Impact factor: 7.397

Review 6.  Effector and regulatory B cells: modulators of CD4+ T cell immunity.

Authors:  Frances E Lund; Troy D Randall
Journal:  Nat Rev Immunol       Date:  2010-03-12       Impact factor: 53.106

7.  Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease.

Authors:  Arezou Khosroshahi; Donald B Bloch; Vikram Deshpande; John H Stone
Journal:  Arthritis Rheum       Date:  2010-06

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

9.  Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.

Authors:  Roberto Stasi; Nichola Cooper; Giovanni Del Poeta; Elisa Stipa; Maria Laura Evangelista; Elisabetta Abruzzese; Sergio Amadori
Journal:  Blood       Date:  2008-03-28       Impact factor: 22.113

10.  Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Gabriella Ferrandina; Ferdinando Coronetta; Francesco Legge; Vanda Salutari; Giovanni Scambia
Journal:  Cancer       Date:  2004-04-01       Impact factor: 6.860
View more
  8 in total

1.  Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency--histologic and immunohistochemical analyses of 16 cases.

Authors:  Nagarjun Rao; A Craig Mackinnon; John M Routes
Journal:  Hum Pathol       Date:  2015-06-01       Impact factor: 3.466

Review 2.  Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Jason A Vander Heiden; Elba Pascual-Goñi; Richard J Nowak; Kevin C O'Connor
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

Review 3.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

Review 4.  B cells and progressive multifocal leukoencephalopathy: search for the missing link.

Authors:  Deniz Durali; Marie-Ghislaine de Goër de Herve; Jacques Gasnault; Yassine Taoufik
Journal:  Front Immunol       Date:  2015-05-19       Impact factor: 7.561

Review 5.  Role of Regulatory Immune Cells and Molecules in Autoimmune Bullous Dermatoses.

Authors:  Tianyu Cao; Shuai Shao; Hui Fang; Bing Li; Gang Wang
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

Review 6.  Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review.

Authors:  Carla Gaggiano; Donato Rigante; Gian Marco Tosi; Antonio Vitale; Bruno Frediani; Salvatore Grosso; Claudia Fabiani; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2019-12-10       Impact factor: 2.980

Review 7.  Myasthenia gravis: a clinical-immunological update.

Authors:  Sophie Binks; Angela Vincent; Jacqueline Palace
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

8.  Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.

Authors:  Joanne Thomas; Sanjana Kuthyar; Jessica G Shantha; Sheila T Angeles-Han; Steven Yeh
Journal:  Ann Eye Sci       Date:  2021-06-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.